Actinium Pharmaceuticals, Inc. (ATNM) › Operating Cash FlowActinium Pharmaceuticals, Inc. (ATNM) — Operating Cash FlowAnnual figures by period end, from SEC filings.2010-12-31: $7.8K2011-12-31: -$517.6K2012-12-31: -$5.21M2013-12-31: -$6.29M2014-12-31: -$14.35M2015-12-31: -$18.54M2016-12-31: -$20.79M2017-12-31: -$21.55M2018-12-31: -$20.57M2019-12-31: -$21.46M2020-12-31: -$21.62M2021-12-31: -$20.87M2022-12-31: $8.64M2023-12-31: -$47.34M2024-12-31: -$33.07M2025-12-31: -$24.58M-$24.58M2010-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$24.58M—2026-03-30From 2025-01-012024-12-31-$33.07M—2026-03-30From 2024-01-012023-12-31-$47.34M-647.6%2025-03-31From 2023-01-012022-12-31$8.64M—2024-03-29From 2022-01-012021-12-31-$20.87M—2023-03-31From 2021-01-012020-12-31-$21.62M—2022-03-25From 2020-01-012019-12-31-$21.46M—2021-03-31From 2019-01-012018-12-31-$20.57M—2020-05-08From 2018-01-012017-12-31-$21.55M—2019-03-15From 2017-01-012016-12-31-$20.79M—2019-03-15From 2016-01-012015-12-31-$18.54M—2018-03-16From 2015-01-012014-12-31-$14.35M—2017-03-16From 2014-01-012013-12-31-$6.29M—2016-03-11From 2013-01-012012-12-31-$5.21M—2014-02-28From 2012-01-012011-12-31-$517.6K-6706.2%2013-03-29From 2011-01-012010-12-31$7.8K—2012-04-12From 2010-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)